Selection of maintenance therapy during first-line treatment of advanced ovarian cancer based on pharmacologic characteristics

References

• Nakai H, Matsumura N. Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs. Int J Clin Oncol. 2022;27(6):1001–1012. doi: 10.1007/s10147-022-02163-3
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–2496. doi: 10.1056/NEJMoa1103799
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–2483. doi: 10.1056/NEJMoa1104390
   PubMed Web of Science ®Google Scholar
• Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–936. doi: 10.1016/S1470-2045(15)00086-8
   PubMed Web of Science ®Google Scholar
• Tewari KS, Burger RA, Enserro D, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol. 2019;37(26):2317–2328. doi: 10.1200/JCO.19.01009
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology; Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer (2023) Version 2. [cited 2023 Aug 26]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf
   Google Scholar
• Zhao L, Claggett B, Tian L, et al. On the restricted mean survival time curve in survival analysis. Biometrics. 2016;72(1):215–221. doi: 10.1111/biom.12384
   PubMed Web of Science ®Google Scholar
• Takamatsu S, Nakai H, Yamaguchi K, et al. Time-dependent changes in risk of progression during use of bevacizumab for ovarian cancer. JAMA Netw Open. 2023;6(8):e2326834. doi: 10.1001/jamanetworkopen.2023.26834
   PubMed Web of Science ®Google Scholar
• Simon T, Gagliano T, Giamas G, et al. Direct effects of anti-angiogenic therapies on tumor cells: VEGF signaling. Trends Mol Med. 2017;23(3):282–292. doi: 10.1016/j.molmed.2017.01.002
   PubMed Web of Science ®Google Scholar
• Sopo M, Anttila M, Hämäläinen K, et al. Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer. BMC Cancer. 2019;19(1):584. doi: 10.1186/s12885-019-5757-3
   PubMedGoogle Scholar
• Guan J, Darb-Esfahani S, Richter R, et al. Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the tumor bank ovarian cancer (TOC) consortium. J Cancer Res Clin Oncol. 2019;145(4):1063–1073. doi: 10.1007/s00432-019-02877-4
   PubMed Web of Science ®Google Scholar
• Nakai H, Matsumura N. The roles and limitations of bevacizumab in the treatment of ovarian cancer. Int J Clin Oncol. 2022;27(7):1120–1126. doi: 10.1007/s10147-022-02169-x
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Joly F, Kristensen G, et al. Optimal treatment duration of Bevacizumab as front-line therapy for advanced ovarian cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT ov-15 open-label randomized phase III trial. J Clin Oncol. 2023;41(4):893–902. doi: 10.1200/JCO.22.01010
   PubMed Web of Science ®Google Scholar
• Colomban O, Tod M, Peron J, et al. Bevacizumab for newly diagnosed ovarian cancers: best candidates among high-risk disease patients (ICON-7). JNCI Cancer Spectr. 2020;4(3):kaa026. doi: 10.1093/jncics/pkaa026
   Web of Science ®Google Scholar
• You B, Purdy C, Copeland LJ, et al. Identification of patients with ovarian cancer experiencing the highest benefit from bevacizumab in the first-line setting on the basis of their tumor-intrinsic chemosensitivity (KELIM): the GOG-0218 validation study. J Clin Oncol. 2022;40(34):3965–3974. doi: 10.1200/JCO.22.01207
   PubMed Web of Science ®Google Scholar
• Tong RT, Boucher Y, Kozin SV, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004;64(11):3731–3736. doi: 10.1158/0008-5472.CAN-04-0074
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Shannon CM, Baumann K, et al. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(5):699–709. doi: 10.1016/S1470-2045(20)30142-X
   PubMed Web of Science ®Google Scholar
• Röhrig F, Vorlová S, Hoffmann H, et al. VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors. Oncogene. 2017;36(1):1–12. doi: 10.1038/onc.2016.182
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Avastin Assessment report, (EMA/CHMP/788079/2011). 2011. [cited 2023 Aug 26]. Available from: https://www.ema.europa.eu/en/documents/variation-report/avastin-h-c-582-ii-0041-epar-assessment-report-variation_en.pdf
   Google Scholar
• Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology/Gynecologic oncology group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(6):779–791. doi: 10.1016/S1470-2045(17)30279-6
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–1308. doi: 10.1200/JCO.2013.51.4489
   PubMed Web of Science ®Google Scholar
• Stockler MR, Hilpert F, Friedlander M, et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014;32(13):1309–1316. doi: 10.1200/JCO.2013.51.4240
   PubMed Web of Science ®Google Scholar
• Marth C, Abreu MH, Andersen KK, et al. Real-life data on treatment and outcomes in advanced ovarian cancer: an observational, multinational cohort study (RESPONSE trial). Cancer. 2022;128(16):3080–3089. doi: 10.1002/cncr.34350
   PubMed Web of Science ®Google Scholar
• Shoji T, Takatori E, Nagasawa T, et al. Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study). Int J Clin Oncol. 2022;27(12):1874–1880. doi: 10.1007/s10147-022-02246-1
   PubMed Web of Science ®Google Scholar
• Fukuda T, Noda T, Uchikura E, et al. Real-world efficacy and safety of Bevacizumab for advanced or recurrent müllerian cancer: a single-institutional experience. Anticancer Res. 2023;43(7):3097–3105. doi: 10.21873/anticanres.16481
   PubMed Web of Science ®Google Scholar
• Verleye L, Castanares-Zapatero D, Devos C, et al. Survival in stage IV ovarian cancer with increased use of debulking surgery and bevacizumab. Int J Gynecol Cancer. 2023;33(4):543–548. doi: 10.1136/ijgc-2022-003813
   PubMed Web of Science ®Google Scholar
• Hettle P, McCrea C, Lee CK, et al. Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer. Ther Adv Med Oncol. 2021;13:17588359211049639. doi: 10.1177/17588359211049639
   Web of Science ®Google Scholar
• Nakai H, Matsumura N. Comment on ‘population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639). 2023;15:17588359231168509. doi: 10.1177/17588359231168509
   Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21. doi: 10.1038/nature03445
   PubMed Web of Science ®Google Scholar
• Murai J, Huang SN, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588–5599. doi: 10.1038/nature03445
   PubMed Web of Science ®Google Scholar
• Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008;451(7182):1116–1120. doi: 10.1038/nature06633
   PubMed Web of Science ®Google Scholar
• Takamatsu S, Brown JB, Yamaguchi K, et al. Utility of homologous recombination deficiency biomarkers across cancer types. JCO Precis Oncol. 2022;6(6):e2200085. doi: 10.1200/PO.22.00085
   PubMedGoogle Scholar
• Birkbak NJ, Wang ZC, Kim JY, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012;2(4):366–375. doi: 10.1158/2159-8290.CD-11-0206
   PubMed Web of Science ®Google Scholar
• Popova T, Manié E, Rieunier G, et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 2012;72(21):5454–5462. doi: 10.1158/0008-5472.CAN-12-1470
   PubMed Web of Science ®Google Scholar
• Abkevich V, Timms KM, Hennessy BT, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012;107(10):1776–1782. doi: 10.1038/bjc.2012.451
   PubMed Web of Science ®Google Scholar
• Telli ML, Timms KM, Reid J, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22(15):3764–3773. doi: 10.1158/1078-0432.CCR-15-2477
   PubMed Web of Science ®Google Scholar
• Takamatsu S, Yoshihara K, Baba T, et al. Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study. Br J Cancer. 2023;128(6):1095–1104. doi: 10.1038/s41416-022-02122-9
   PubMed Web of Science ®Google Scholar
• Takaya H, Nakai H, Takamatsu S, et al. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. Sci Rep. 2020;10(1):2757. doi: 10.1038/s41598-020-59671-3
   PubMed Web of Science ®Google Scholar
• Hoppe MH, Jaynes P, Wardyn JD, et al. Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer. EMBO Mol Med. 2021;13(5):e13366. doi: 10.15252/emmm.202013366
   PubMed Web of Science ®Google Scholar
• Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381(25):2403–2415. doi: 10.1056/NEJMoa1909707
   PubMed Web of Science ®Google Scholar
• Karst AM, Jones PM, Vena N, et al. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube–derived high-grade serous ovarian cancers. Cancer Res. 2014;74(4):1141–1152. doi: 10.1158/0008-5472.CAN-13-2247
   PubMed Web of Science ®Google Scholar
• Etemadmoghadam D, Weir BA, Au-Yeung G, et al. Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc Natl Acad Sci U S A. 2013;110(48):19489–19494. doi: 10.1073/pnas.1314302110
   PubMed Web of Science ®Google Scholar
• Ekumi KM, Paculova H, Lenasi T, et al. Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex. Nucleic Acids Res. 2015;43(5):2575–2589. doi: 10.1093/nar/gkv101
   PubMed Web of Science ®Google Scholar
• Joshi PM, Sutor SL, Huntoon CJ, et al. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. J Biol Chem. 2014;289(13):9247–9253. doi: 10.1074/jbc.M114.551143
   PubMed Web of Science ®Google Scholar
• Funnell T, O’Flanagan CH, Williams MJ, et al. Single-cell genomic variation induced by mutational processes in cancer. Nature. 2022;612(7938):106–115. doi: 10.1038/s41586-022-05249-0
   PubMed Web of Science ®Google Scholar
• Li H, Liu ZY, Wu N, et al. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer. 2020;19(1):107. doi: 10.1186/s12943-020-01227-0
   PubMed Web of Science ®Google Scholar
• Hopkins TA, Shi Y, Rodriguez LE, et al. Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors. Mol Cancer Res. 2015;13(11):1465–1477. doi: 10.1158/1541-7786.MCR-15-0191-T
   PubMed Web of Science ®Google Scholar
• Zandarashvili L, Langelier MF, Velagapudi UK, et al. Structural basis for allosteric PARP-1 retention on DNA breaks. Science. 2020;368(6486):eaax6367. doi: 10.1126/science.aax6367
   PubMed Web of Science ®Google Scholar
• Onji H, Murai J. Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes. Cancer Sci. 2022;113(9):2943–2951. doi: 10.1111/cas.15477
   PubMed Web of Science ®Google Scholar
• Patch AM, Christie EL, Etemadmoghadam D, et al. Whole–genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489–494. doi: 10.1038/nature14410
   PubMed Web of Science ®Google Scholar
• Kondrashova O, Topp M, Nesic K, et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. 2018;9(1):3970. doi: 10.1038/s41467-018-05564-z
   PubMedGoogle Scholar
• Lin KK, Harrell MI, Oza AM, et al. BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2019;9(2):210–219. doi: 10.1158/2159-8290.CD-18-0715
   PubMed Web of Science ®Google Scholar
• Borst P, Schinkel AH. P-glycoprotein ABCB1: a major player in drug handling by mammals. J Clin Invest. 2013;123(10):4131–4133. doi: 10.1172/JCI70430
   PubMed Web of Science ®Google Scholar
• Lheureux S, Oaknin A, Garg S, et al. EVOLVE: a multicenter open-label single-arm clinical and translational phase II trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression. Clin Cancer Res. 2020;26(16):4206–4215. doi: 10.1158/1078-0432.CCR-19-4121
   PubMed Web of Science ®Google Scholar
• Gu S, Lheureux S, Sayad A, et al. Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening. Proc Natl Acad Sci U S A. 2021;118(25):e2026663118. doi: 10.1073/pnas.2026663118
   PubMed Web of Science ®Google Scholar
• Takamatsu S, Murakami K, Matsumura N. Homologous recombination deficiency in cell line libraries does not correlate with in vitro sensitivity to platinum agents or PARP inhibitors. bioRxiv. 2023. [published online 7 Jul 2023]. doi: 10.1101/2023.07.06.547853
   Google Scholar
• Sun K, Mikule K, Wang Z, et al. A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models. Oncotarget. 2018;9(98):37080–37096. doi: 10.18632/oncotarget.26354
   PubMedGoogle Scholar
• PMDA. Lynparza® drug interview form, 11th edition, 2023. [cited 2023 Aug 26]. Available from: https://www2.astrazeneca.co.jp/product/di.asp?pr_kikaku_id=LYN100&di_type=02
   Google Scholar
• PMDA. Zejula® drug interview form, 3rd edition, 2023. [cited 2023 Aug 26]. Available from: https://www.info.pmda.go.jp/go/pack/4291068F1028_1_03/4291068F1028_1_03?view=body&lang=ja
   Google Scholar
• Martins MLF, Loos NHC, Mucuk S, et al. P-Glycoprotein (ABCB1/MDR1) controls brain penetration and intestinal disposition of the PARP1/2 inhibitor niraparib. Mol Pharm. 2021;18(12):4371–4384. doi: 10.1021/acs.molpharmaceut.1c00553
   PubMedGoogle Scholar
• Gray S, Khor XY, Yiannakis D. Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases. BMJ Case Rep. 2019;12(8):e230738. doi: 10.1136/bcr-2019-230738
   PubMedGoogle Scholar
• Wang Q, Zhang F, Gao H, et al. Successful treatment of a patient with brain metastases from endometrial cancer using niraparib: a case report. Ann Palliat Med. 2021;10(1):818–827. doi: 10.21037/apm-21-113
   PubMed Web of Science ®Google Scholar
• Ning J, Wakimoto H. Therapeutic application of PARP inhibitors in neuro-oncology. Trends Cancer. 2020;6(2):147–159. doi: 10.1016/j.trecan.2019.12.004
   PubMed Web of Science ®Google Scholar
• Banerjee S, Moore KN, Colombo N, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1721–1731. doi: 10.1016/S1470-2045(21)00531-3
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Leary A, Pignata S, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol. 2023;34(8):681–692. doi: 10.1016/j.annonc.2023.05.005
   PubMed Web of Science ®Google Scholar
• González-Martín A, Pothuri B, Vergote I, et al. Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer. 2023;189:112908. doi: 10.1016/j.ejca.2023.04.024
   PubMed Web of Science ®Google Scholar
• Li N, Zhu J, Yin R, et al. Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2023;9(9):1230–1237. doi: 10.1001/jamaoncol.2023.2283
   PubMed Web of Science ®Google Scholar
• Chen D, Shao M, Meng P, et al. GSA: an independent development algorithm for calling copy number and detecting homologous recombination deficiency (HRD) from target capture sequencing. BMC Bioinf. 2021;22(1):562. doi: 10.1186/s12859-021-04487-9
   PubMed Web of Science ®Google Scholar
• DiSilvestro P, Colombo N, Scambia G, et al. Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. J Clin Oncol. 2020;38(30):3528–3537. doi: 10.1200/JCO.20.00799
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416–2428. doi: 10.1056/NEJMoa1911361
   PubMed Web of Science ®Google Scholar
• O’Cearbhaill RE, Pérez-Fidalgo JA, Monk BJ, et al. Efficacy of niraparib by time of surgery and postoperative residual disease status: a post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. Gynecol Oncol. 2022;166(1):36–43. doi: 10.1016/j.ygyno.2022.04.012
   PubMed Web of Science ®Google Scholar
• González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–2402. doi: 10.1056/NEJMoa1910962
   PubMed Web of Science ®Google Scholar
• Fuh KC, Shin JY, Kapp DS, et al. Survival differences of Asian and caucasian epithelial ovarian cancer patients in the United States. Gynecol Oncol. 2015;136(3):491–497. doi: 10.1016/j.ygyno.2014.10.009
   PubMed Web of Science ®Google Scholar
• Fuh KC, Java JJ, Chan JK, et al. Differences in presentation and survival of Asians compared to caucasians with ovarian cancer: an NRG oncology/GOG ancillary study of 7914 patients. Gynecol Oncol. 2019;154(2):420–425. doi: 10.1016/j.ygyno.2019.05.013
   PubMed Web of Science ®Google Scholar
• Gandara DR, Kawaguchi T, Crowley J, et al. Japanese-US Common-arm analysis of paclitaxel plus carboplatin in advanced non–small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009;27(21):3540–3546. doi: 10.1200/JCO.2008.20.8793
   PubMed Web of Science ®Google Scholar
• Harter P, Mouret-Reynier MA, Pignata S, et al. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. Gynecol Oncol. 2022;164(2):254–264. doi: 10.1016/j.ygyno.2021.12.016
   PubMed Web of Science ®Google Scholar
• Pan L, Wu L, Zhu J, et al. Niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a post hoc analysis on efficacy by surgical timing and residual disease status in the phase III PRIME trial. ESMO Open. 2023;8(suppl 1; abstr 37MO):100817. doi: 10.1016/j.esmoop.2023.100817
   Google Scholar
• Niraparib vs niraparib plus bevacizumab in patients with platinum/taxane-based chemotherapy in advanced ovarian cancer. ClinicalTrials.Gov Identifier: NCT05009082. [cited 2023 Aug 26]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT05009082
   Google Scholar
• Harter P, Trillsch F, Okamoto A, et al. Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBrcam): results from the randomized, placebo (pbo)-controlled phase III DUO-O trial. J Clin Oncol. 2023;41(suppl 17; abstr LBA5506). doi: 10.1200/JCO.2023.41.17_suppl.LBA5506
   Web of Science ®Google Scholar
• Study of chemotherapy with pembrolizumab (MK-3475) followed by maintenance with olaparib (MK-7339) for the first-line treatment of women with BRCA non-mutated advanced epithelial ovarian cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036). ClinicalTrials.Gov Identifier: NCT03740165. Avaibale from: https://clinicaltrials.gov/study/NCT03740165
   Google Scholar
• Kaplan AR, Gueble SE, Liu Y, et al. Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51. Sci Transl Med. 2019;11(492):eaav4508. doi: 10.1126/scitranslmed.aav4508
   PubMed Web of Science ®Google Scholar
• Ding L, Kim HJ, Wang Q, et al. PARP inhibition elicits STING-Dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep. 2018;25(11):2972–2980. doi: 10.1016/j.celrep.2018.11.054
   PubMed Web of Science ®Google Scholar
• Wu YM, Cieślik M, Lonigro RJ, et al. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell. 2018;173(7):1770–1782. doi: 10.1016/j.cell.2018.04.034
   PubMed Web of Science ®Google Scholar